Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.70 |
| ▸ | FLT3 | P36888 | 7/20 | 0.58 |
| ▸ | KIT | P10721 | 6/20 | 0.58 |
| ▸ | CSF1R | P07333 | 5/20 | 0.56 |
| ▸ | FLT1 | P17948 | 5/20 | 0.56 |
| ▸ | LCK | P06239 | 4/20 | 0.56 |
| ▸ | FYN | P06241 | 4/20 | 0.56 |
| ▸ | LYN | P07948 | 4/20 | 0.56 |
| ▸ | SRC | P12931 | 4/20 | 0.56 |
| ▸ | FLT4 | P35916 | 4/20 | 0.56 |
| ▸ | BLK | P51451 | 4/20 | 0.56 |
| ▸ | ABL1 | P00519 | 3/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.55 |
| ▸ | LTK | P29376 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14160125 | 0.89 | KDR (0.55) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL13873001 | 0.86 | KDR (0.69) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL13873228 | 0.85 | AURKB (0.58) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL13873278 | 0.84 | KDR (0.54) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL2817665 | 0.83 | KDR (0.68) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL13209956 | 0.82 | KDR (0.80) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL1702799 | 0.82 | KDR (1.00) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL13873089 | 0.82 | KDR (0.62) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL3842668 | 0.80 | KDR (0.59) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL12973354 | 0.80 | KDR (0.55) | KDRFLT3KITCSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | KDR, FLT4, TIE1 | KDR 1/4885FLT3 143/4885KIT 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.